Alzinova

2.74

SEK

-2.14 %

Less than 1K followers

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

-2.14%

-6.8%

-20.81%

-27.51%

-27.13%

+74.92%

-25.44%

-45.23%

-61.79%

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools in the work area. The largest operations are in the Nordic market. The company was founded in 2011 and is headquartered in Gothenburg.

Market cap

244.31M SEK

Turnover

363.27K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

15.5

2025

Interim report Q1'25

28.5

2025

General meeting '25

21.8

2025

Interim report Q2'25

ShowingAll content types

Regulatory press release3/7/2025, 10:53 AM

Bulletin from the Extraordinary General Meeting of Alzinova AB (publ)

Press release2/27/2025, 8:55 AM

Redeye: Alzinova Q4 - Bolstered by clinical progress

Regulatory press release2/27/2025, 6:30 AM

Alzinova publishes year-end report 2024

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release2/19/2025, 12:15 PM

Carnegie Access: Alzinova: Data from high-dose cohort in Phase Ib trial

Regulatory press release2/19/2025, 7:00 AM

A higher dose of ALZ-101 also shows good safety and tolerability

Regulatory press release2/18/2025, 7:00 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN ALZINOVA AB (publ)

Press release2/3/2025, 6:30 AM

All study participants have completed the final visit in the Phase 1 study

Regulatory press release1/28/2025, 3:19 PM

Alzinova strategically realigns CMO position to enhance collaboration and drive next development phase

Press release1/27/2025, 6:35 AM

Carnegie Access: Alzinova: Approaching several triggers in 2025

Press release1/21/2025, 10:05 AM

Successful participation at the J.P. Morgan Healthcare Conference in San Francisco

Regulatory press release12/20/2024, 2:00 PM

Alzinova publishes financial calendar for 2025

Regulatory press release12/20/2024, 12:30 PM

Alzinova appoints Erik Kullgren as permanent CFO

Press release12/12/2024, 12:00 PM

Alzinova attends J.P. Morgan Healthcare Conference in San Francisco for meetings with industry partners and investors

Regulatory press release12/9/2024, 6:30 AM

Alzinova reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease

Press release11/22/2024, 7:35 AM

Alzinova presents at Carnegie SME day

Press release11/14/2024, 2:25 PM

Redeye: Alzinova Q3 - A new sheriff in town

Regulatory press release11/14/2024, 7:37 AM

Alzinova publishes interim report January – September 2024

Press release11/11/2024, 7:45 AM

Patient data from the extension part of Alzinova's phase 1b study with ALZ-101 is being processed

Press release10/31/2024, 7:45 AM

Alzinova to attend BIO-Europe 2024 - Europe's leading partnering conference for the life science industry

Press release10/28/2024, 7:45 AM

Alzinova - All patients in the high dose cohort of the phase 1b study have received their last dose

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.